Last update 06 Aug 2026

IBI3028

Overview

Basic Info

Drug Type
Dual payload Antibody drug conjugate (Dual payload ADC)
Synonyms
PF-08714640
Target
EGFR x c-Met
Action
antagonists, inhibitors
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Colorectal CancerLocally Advanced Malignant Solid NeoplasmNon-Small Cell Lung Cancer+ [4]
Inactive Indication-
Originator Organization
Innovent Biologics, Inc.Innovent Biologics, Inc.
Active Organization
Innovent Biomedical Technology (Hangzhou) Co., Ltd.Innovent Biologics, Inc.Innovent Biologics, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with IBI3028
NCT07589205
/ RecruitingPhase 1
A Phase 1, Multi-Center, Open-Label Study Evaluating IBI3028 Treatment in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
100 Clinical Results associated with IBI3028
Login to view more data
100 Translational Medicine associated with IBI3028
Login to view more data
100 Patents (Medical) associated with IBI3028
Login to view more data
100 Deals associated with IBI3028
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 1
China
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
31 Mar 2026
Locally Advanced Malignant Solid NeoplasmPhase 1
China
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
31 Mar 2026
Non-Small Cell Lung CancerPhase 1
China
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
31 Mar 2026
Pancreatic Ductal AdenocarcinomaPhase 1
China
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
31 Mar 2026
Squamous Cell Carcinoma of Head and NeckPhase 1
China
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
31 Mar 2026
Locally Advanced Malignant NeoplasmIND Approval
China
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
29 Jan 2026
NeoplasmsPreclinical
China
Innovent Biologics, Inc.Innovent Biologics, Inc.
28 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free